NL-OMON52738尚未招募2 期
ong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies (study 208750) - 208750
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Had at least one dose of Adoptive Cell Therapies in the parent study.
- •Have either completed the interventional study or have withdrawn from it.
- •Contraception guidelines for males and females should be followed, see
- •chapter 5.1 of the protocol for details.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
ong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapieson-small cell lung cancer (NSCLC), Multiple Myeloma & other indications, Synovial sarcoma, Myxoid/round cell liposarcoma (MRCLS)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10073137Term: Myxoid liposarcoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10042863Term: Synovial sarcoma Class: 100000004864CTIS2024-513033-21-00Adaptimmune LLC76
进行中（未招募）
1 期
Adoptive cell therapy LTFU studySynovial sarcomaMultiple myelomaNon-small cell lung cancerMyxoid liposarcomaMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004888-31-NLGlaxoSmithKline research & development Ltd.171
进行中（未招募）
1 期
Adoptive cell therapy LTFU studySynovial sarcoma, Non-small cell lung cancer (NSCLC), Myxoid/round cell liposarcoma (MRCLS), Multiple Myeloma & other indicationsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004888-31-FRGlaxoSmithKline Research & Development Ltd171
进行中（未招募）
1 期
Adoptive cell therapy LTFU studySynovial sarcoma, Non-small cell lung cancer (NSCLC), Myxoid/round cell liposarcoma (MRCLS), Multiple Myeloma & other indicationsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004888-31-SEAdaptimmune LLC171
进行中（未招募）
1 期
ong term follow-up clinical trial to the MUST trial which investigates which treatment of systemic steroid treatment and a steroid implant which is inserted into the eye gives the best visual outcome for patients with chronic eye inflammation.EUCTR2011-001078-25-GBational Institute of Health, National Eye Institute250